为您找到"
dxp-604
"相关结果约100,000,000个
Moreover, DXP-604 reduced the invasive mechanical ventilation and mortality of high-risk SARS-CoV-2 infected patients. The ongoing clinical trials of DXP-604 neutralizing antibody will clarify its utility as a new attractive countermeasure for high-risk COVID-19.
Importantly, converting IgG to dimeric and secretory forms of IgA restores neutralizing ability against Omicron variants. When administered intranasally, the dimeric IgA antibody DXP-604 provided both prophylactic and therapeutic protection against Omicron BA.5 in transgenic mice expressing human ACE2.
记者今日从北京地坛医院获悉，北京35例患者使用接受了我国自主研发的中和抗体药物DXP-604的"同情用药"后，短期内病情即获得明显好转。 截至11月19日，已有17名患者顺利出院。
Description: Research Grade DXP-604 is a fully human monoclonal antibody with strong in vitro and in vivo neutralizing activity to SARS-COV-2
Clinical observation of neutralizing antibody DXP-604 for treatment critical COVID-19 patients infected with SARS-CoV-2 Delta variant.
Under the terms of the agreement, Singlomics has granted BeiGene exclusive rights in ex- China territory to develop, manufacture, and commercialize its preclinical assets DXP-593 and DXP-604, as ...
The binding affinity of DXP-604 against the Omicron RBD is markedly reduced compared to the wild-type RBD; nonetheless, it can still neutralize Omicron at an IC 50 of 287 ng ml −1 —a reduction ...
DXP-604 can block Covid-19 variants with a single antibody, while its production costs less than one-third of dual antibody drugs, said Sunney Xie, the leader of the research and development team and a professor at Peking University.
Importantly, the dimeric or secretory IgA1 form of the DXP-604 antibody significantly outperformed its parental IgG antibody, and neutralized the Omicron lineages BA.1, BA.2, and BA.4/5 with a 25- to 75-fold increase in potency.
Importantly, the dimeric or secretory IgA1 form of the DXP-604 antibody significantly outperformed its parental IgG antibody, and neutralized the Omicron lineages BA.1, BA.2 and BA.4/5 with a 50-150-fold increase in potency, reaching the level of the most potent monoclonal antibodies described till date.